本帖最后由 老马 于 2012-1-13 21:20 编辑
B3 M$ |% p6 E$ a2 ~9 k' F. ^. ]
爱必妥和阿瓦斯丁的比较
4 ?0 a9 `# y$ Z( ^" V
7 e# x7 ^ V+ s6 O mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) l5 M( N9 u/ \- H4 m
( h: O; A, G- S0 e& V% n2 P
( k5 W# y+ [% S' y, chttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: c8 g3 h6 s" V$ j( c
==================================================, ^+ z# K. q( X7 b. h3 ]$ P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
$ S" l* A$ W7 E( d, mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 N; n2 c, `' n& q! @8 \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; B" f" j/ |/ C& u4 s
|
显身卡
$ e2 G7 R1 w* z. l/ q. @
